English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Skin lesions in immunosuppressed cancer patients have a broad differential of infectious and non-infectious causes. Rash may be an early indication of serious systemic infections that are otherwise difficult to diagnose; hence, skin biopsy with culture and histopathology plays a vital role in establishing a diagnosis. Our study aims to determine the yield of skin biopsy in identifying infections and its impact on diagnosis and therapy. Methods We performed a retrospective review of all cancer patients admitted to University of Maryland from August 2010 to October 2017 who had a skin biopsy for new rash. We classified the skin lesion as infectious if the biopsy pathology or culture showed a pathogenic organism. Results Of 269 patients biopsied for new skin lesions, 43 (16%) were caused by infection and 226 (84%) were non-infectious. Among non-infectious causes, 63% were due to graft vs. host disease, 9% cancer, 9% drug reaction, 4% Sweet syndrome, and 29% were nondiagnostic. The median WBC count trended toward significantly lower in the infectious group (1,100/μL) vs. the non-infectious group (2,700/μL; P = 0.08). Of the 43 infectious lesions, 21 (49%) were fungal, 13 (30%) bacterial, seven (16%) viral and one (2%) mycobacterial. Sixty-seven percent patients had absolute neutrophil counts <1,000/μL, 40% were febrile, and 28% had had a stem cell transplant. The majority of infections (58%) were identified by skin biopsy alone. Change in diagnosis after biopsy was significantly more likely in patients with infectious cause of skin lesions than non-infectious (47% vs. 28%, respectively, P < 0.02). Patients with a biopsy-confirmed infectious cause were five times (95% CI 2.70–10.22) more likely to have a change in therapy post biopsy compared with patients with a non-infectious cause. The sensitivity and specificity of provider diagnosis prior to biopsy was 86 and 81%, respectively. The positive predictive value of pre-biopsy provider diagnosis was low at 46%. Conclusion Skin biopsy of new rash in immunocompromised cancer patients frequently reveals systemic infections (especially fungal) and often leads to a change in diagnosis and therapeutic management. Disclosures All authors: No reported disclosures.

1562. Impact of Skin Biopsy on Diagnosing Infections and Changing Treatment in Cancer Patients with New Skin Rash